1. Home
  2. Live Updates
  3. சீன தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல்

Live Breaking News & Updates on சீன தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல்

Stay updated with breaking news from சீன தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AstraZeneca PLC bullish on outlook as no-profit COVID-19 vaccine delivers US$275mln quarterly sales


The pharma giant said the second half will see a boost in performance
AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine has delivered sales of US$275mln in the first quarter as it made a bullish statement on its outlook.
The pharma giant expects a performance boost in the second half of 2021 as vaccine rollouts and lower infections will reduce the hit of the pandemic on trading.
Chief executive Pascal Soriot reiterated full-year guidance for the pharma giant after first-quarter figures were in line with expectations.
Total revenue for the year is estimated to jump 11-12%, with core earnings per share (EPS) coming in at US$4.75-5. ....

Neil Shah , Pascal Soriot , Chinese National Reimbursement Drug List , Edison Group , Olympia Phase , Big Caps , Harma Biotech , Lon Azn , நீல் ஷா , சீன தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் , எடிசன் குழு , ஒலிம்பியா கட்டம் , பெரியது தொப்பிகள் ,

AstraZeneca PLC expects performance boost in second half after posting 15% quarterly revenue jump


The pharma giant said the second half will see a boost in performance
AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine has delivered sales of US$275mln in the first quarter as it made a bullish statement on its outlook.
The pharma giant expects a performance boost in the second half of 2021 as vaccine rollouts and lower infections will reduce the hit of the pandemic on trading.
Chief executive Pascal Soriot reiterated full-year guidance for the pharma giant after first-quarter figures were in line with expectations.
Total revenue for the year is estimated to jump 11-12%, with core earnings per share (EPS) coming in at US$4.75-5. ....

Pascal Soriot , Chinese National Reimbursement Drug List , Olympia Phase , சீன தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் , ஒலிம்பியா கட்டம் ,